Which peptides have been studied in dermatological & pigmentation research?
-
Afamelanotide
Synthetic alpha-MSH analogue studied in erythropoietic protoporphyria (EPP). Licensed in the UK for adults with EPP; not recommended for routine NHS use. Not the same as Melanotan II.
ModerateLicensed UK medicine -
Melanotan IIMT-II
Synthetic melanocortin receptor agonist studied for skin tanning. Not licensed in the UK; human evidence is a three-volunteer pilot plus case reports.
LimitedNot licensed in the UK
Best recorded finding for each peptide in this area
| Peptide | UK status | Finding | Study type | Evidence grade |
|---|---|---|---|---|
| Afamelanotide | Licensed UK medicine | Two phase 3 trials in EPP | Human trial | Moderate |
| Melanotan II | Not licensed in the UK | Naevi and melanoma case reports | Human observational | Limited |
About this research area
"Dermatological & Pigmentation Research" groups peptides studied for effects on skin pigmentation, melanogenesis and related dermatological outcomes, including both the mechanisms driving pigmentation change and the safety literature examining pigmented-lesion changes associated with that mechanism. Evidence in this category includes early-phase human dosing studies alongside case reports and case-series safety literature published in the dermatology field. This category currently reflects a narrow evidence base and is expected to broaden as further peptides researched in this area are added to the catalogue.
8 sources in the library relate to this area. See them.
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.